AsemconnectVietnam - ASKA Pharmaceutical completed increasing its ownership in Ha Tay Pharmaceutical (DHT) to nearly 33%; OPC Pharmaceuticals (OPC) tobe fined and had tax arrears of more than VND1.18 billion; Imexpharm (IMP) reaches VND377 billion pre-tax profit in 2023, up 29%.

ASKA Pharmaceutical Group
ASKA Pharmaceutical Group - a pharmaceutical giant in Japan has just announced that it has increased its ownership in Ha Tay Pharmaceutical Joint Stock Company (code DHT - HNX exchange) to 32.56% through a private placement.
Ha Tay Pharmaceutical recently announced that it has completed the private offering of 8.4 million shares, equivalent to 11.36% of the total outstanding shares to ASKA Pharmaceutical Co., Ltd, thereby increasing its charter capital to more than VND877 billion. With the offering price of 21,500 VND/share, it is estimated that the Japanese giant spent about VND180.6 billion for the above shares.
After purchasing all the shares from the offering, ASKA Pharmaceutical increased its ownership in Ha Tay Pharmaceutical from 18.41 million shares (ratio 24.9%) to 25.8 million shares (ratio 32.56%). Of these, 8.4 million individual shares will be restricted from transfer within 3 years.
As for the proceeds, Ha Tay Pharmaceutical will use more than VND78.3 billion for the Hataphar high-tech pharmaceutical factory project and VND102.2 billion to restructure bank loans to increase capital autonomy, reducing financial pressure for the Company.
ASKA Pharmaceutical is a pharmaceutical company established over 100 years ago with headquarters in Tokyo, Japan. The Group's main business lines are manufacturing, trading and importing and exporting pharmaceuticals, medicines, medical equipment...
Regarding the business situation of Ha Tay Pharmaceutical, in the first 9 months of 2023, the Company recorded net revenue of VND1,525 billion and profit after tax of VND72.1 billion, an increase of 17% and 15% respectively compared to the previous year. Profit after tax of the parent company reached VND69.5 billion.
In 2023, Ha Tay Pharmaceutical sets a business plan with a revenue target of VND1,600 billion and pre-tax profit of VND80 billion. With 9-month results reaching VND89.6 billion in profit before tax, the Company has exceeded the yearly profit target by 12%.
OPC Pharmaceuticals (OPC)
The General Department of Taxation has just decided to sanction tax administrative violations against OPC Pharmaceutical Joint Stock Company (stock code OPC - HOSE).
OPC Pharmaceutical Company committed false declarations leading to a lack of tax payable, as stipulated in Point a, Clause 1, Article 16 of Decree No. 125/2020/ND-CP.
Based on the violation, the General Department of Taxation has decided to force the full payment of the missing corporate income tax amount to the budget of VND917.8 million (it is VND88.3 million in 2021 and VND829.5 million in 2022); Late payment interest on corporate income tax is VND79.06 million.
Thus, the total amount of tax arrears, fines and late payment interest is more than VND1.18 billion.
"Within 10 days from the date of receiving the decision, Ms. Pham Thi Xuan Huong, General Director of OPC Pharmaceutical Company must strictly comply with the penalty decision and pay money to the State Treasury of Ho Chi Minh City", General Director The Tax Department emphasized.
According to research, OPC Pharmaceutical Company, formerly known as Central Pharmaceutical Enterprise 26 - OPC, was established on October 24, 1977. The main business areas of the enterprise include growing and processing medicinal herbs; Producing and trading in pharmaceuticals, supplies, machinery, medical equipment, chemicals, cosmetics, food and other products; Import and export of non-medicinal products.
Regarding shareholder structure, in the most recent shareholder update as of March 30, 2023, OPC Pharmaceutical Company has 4 major shareholders including PVI Opportunity Investment Fund owning 17.38% of charter capital; Shareholder Trinh Xuan Vuong owns 13.62% of charter capital; Vietnam Pharmaceutical Corporation - Joint Stock Company (code DVN - UPCoM) owns 13.4% of charter capital; Pacific Partners Joint Stock Company owns 12.86% of charter capital; and the remaining 42.74% of charter capital belongs to the group of shareholders owning less than 5% of charter capital.
Imexpharm (IMP) reaches VND377 billion pre-tax profit in 2023, up 29%
Imexpharm Pharmaceutical Joint Stock Company (stock code IMP - HOSE) has just announced the situation of production and business activities in 2023.
Accordingly, in 2023, the Company will achieve net revenue of VND1,994 billion, an increase of 21% over the same period and exceeding the yearly plan by 14% thanks to the contribution of 53% from the OTC channel and 42.7% from the ETC channel. Of which, OTC revenue increased by 8% over the same period thanks to efforts to retain customers, expand the network and strong growth of key products. ETC revenue grew 40% over the same period thanks to the recovery of hospitals and expanded product portfolio.
Antibiotics are still IMP's core strength and contribute 74% to total revenue. IMP said that the Company is taking active measures to increase revenue from non-antibiotic drugs.
EU-GMP factories (IMP2, IMP3 and IMP4) with product portfolios targeting the ETC channel contributed higher to revenue and profit thanks to increased operating capacity.
Pre-tax profit in 2023 will reach VND377 billion, up 29% over the same period and exceeding the yearly plan by 8%. EBITDA margin (earnings before interest, taxes and depreciation) in 2023 improved from 22% to 23% thanks to strong revenue growth leading to better economies of scale and higher operating leverage as well as effective cost-saving initiatives.
In 2024, IMP plans to expand MA EU group 1 (product registration number in Europe); global business development; import, technology transfer and innovation initiatives.
Vietnam Pharmaceutical (DVN)
Pre-tax profit reached VND436 billion, an increase of 230% over the same period last year and equal to 130% of the 2023 plan.
Vietnam Pharmaceutical Corporation (Vinapharm - DVN code: UPCoM) said that the total revenue realized in 2023 reached VND306 billion, an increase of 74% compared to realized in 2022 and reaching 110% compared to the plan; Pre-tax profit is expected to reach VND222 billion, up 705% over the same period and reaching 105% of the plan.
Vinapharm's consolidation results show that total revenue is estimated at VND5,664 billion, equivalent to 2022 and reaching 96% of the plan. Pre-tax profit reached VND436 billion, an increase of 230% over the same period last year and equal to 130% of the 2023 plan.
Vinapharm has completed the development of a restructuring project with the goal of optimizing business operations, management and promoting sharing in SCIC's pharmaceutical portfolio.
In 2024, Vinapharm sets a revenue plan according to the general financial report of VND319 billion, an increase of 4% and pre-tax profit of VND254 billion, an increase of 14% compared to the estimate for 2023. Revenue according to the financial report Vinapharm's consolidated capital in 2024 is expected to be VND5,903 billion, equivalent to a 4% increase compared to the estimate for 2023. Pre-tax profit is expected to be VND524 billion, equivalent to an increase of 20% compared to the estimate for 2023.
N.Nga
Source: VITIC/Tinnhanhchungkhoan